Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.

@article{Gerloni2008FocusOA,
  title={Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.},
  author={Valeria Maria Gerloni and Irene Pontikaki and Maurizio Gattinara and Flavio Fantini},
  journal={Annals of the rheumatic diseases},
  year={2008},
  volume={67 8},
  pages={1145-52}
}
OBJECTIVE To report adverse events (AEs) seen in a large cohort of patients with juvenile idiopathic arthritis (JIA) treated with tumour necrosis factor (TNF)alpha blockers (infliximab and etanercept). METHODS All patients with JIA treated with infliximab or etanercept at the Paediatric Rheumatologic Centre of the G Pini Institute (Milan, Italy) from November 1999 to February 2006, were enrolled in an open, single-centre, long-term prospective study RESULTS In all, 163 patients (68… CONTINUE READING